Sinovac +5.3% AH. Trial results published in journal.

|About: Sinovac Biotech, Ltd. (SVA)|By:, SA News Editor

Phase III trial results for Sinovac's (SVA) EV71 vaccine have been published in the Feb. 27 issue of the New England Journal of Medicine. (PR)

Sinovac says the results show EV71 had a 94.8% efficacy rate against EV71-related hand, foot, and mouth disease, and a 100% efficacy rate "against EV71-associated hospitalization and against HFMD with neurologic complications."